00:43 , Jun 14, 2019 |  BC Extra  |  Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
18:35 , Jun 7, 2019 |  BC Extra  |  Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
18:43 , May 22, 2019 |  BC Extra  |  Company News

AlloVir, first to test ElevateBio's model, raises $120M ahead of Phase III

The first disclosed company that will test newly launched ElevateBio's cell and gene therapy model is antiviral treatment developer AlloVir, which revealed the companies' relationship along with a $120 million series B round on Wednesday....
20:52 , May 8, 2019 |  BC Extra  |  Company News

Take2 licenses Grail’s nasopharyngeal cancer detection platform

Grail Inc. (Menlo Park, Calif.) granted Take2 Health Ltd. (Hong Kong, China) exclusive, worldwide rights to a portfolio of technology for the early detection of nasopharyngeal cancer. Financial terms were not disclosed. Grail spokesperson Charlotte...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
22:50 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Viral gH, gL and gp42 as new Epstein-Barr virus vaccine targets

DISEASE CATEGORY: Infectious disease INDICATION: Epstein-Barr virus (EBV) Cell culture, mouse and macaque studies suggest vaccines based on EBV gH, gL and gp42 could help prevent EBV infection. The vaccines consist of self-assembling protein nanoparticles...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
18:02 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

EBNA1 inhibitors for EBV-dependent cancers

DISEASE CATEGORY: Cancer INDICATION: Nasopharyngeal cancer; lymphoma In vitro , cell culture and mouse studies identified two prodrugs of phenylacetylenyl benzoic acid-based EBNA1 inhibitors that could help treat EBV-dependent lymphoma and nasopharyngeal cancer. Fragment-based screening,...
14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
15:49 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting RAB27A-dependent formation of CD19-positive extracellular vesicles could enhance the efficacy of chemotherapy for colorectal cancer. In serum samples from colorectal cancer patients, levels of CD19-positive...